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464 The Journal of Thoracic and Cardbjectives: The incidence of patient–prosthesis mismatch after mitral valve replace-
ent and its effect on late outcomes have remained unclear. This study was
onducted to determine the impact of patient–prosthesis mismatch on recurrent
ongestive heart failure, postoperative pulmonary hypertension, and late survival
fter mitral valve replacement.
ethods: Between 1985 and 2005, 884 patients, with a mean age 63  12 years,
nderwent mitral valve replacement (657 mechanical, 227 bioprosthesis) with
ontemporary prostheses. Mean clinical and echocardiographic follow-up was 5.1
.1 years (4344 patient-years). Patient–prosthesis mismatch was defined as an
ndexed effective orifice area of 1.25 cm2/m2 or less. Parametric and nonparametric
nalyses were used to determine predictors of outcomes.
esults: The incidence of patient–prosthesis mismatch was 32%. Predictors of
ecurrent congestive heart failure included low indexed effective orifice area, low
jection fraction, elevated postoperative mean mitral gradient, and use of a biopros-
hesis (P  .05). Postoperative pulmonary hypertension was associated with small
itral size, elevated mean mitral gradient, low ejection fraction, and atrial fibrilla-
ion (P  .05); indexed effective orifice area did not predict postoperative pulmo-
ary hypertension (P  .89). Poor late survival was predicted by low indexed
ffective orifice area (1.25 cm2/m2), New York Heart Association class 3 or 4,
levated right ventricular pressure, stroke, older age, coronary artery disease, and
ioprosthesis use (P  .05). Survival for patients with patient–prosthesis mismatch
ersus those without patient–prosthesis mismatch at 1, 3, 5, and 10 years was 91%
ersus 95%, 85% versus 90%, 78% versus 86%, and 65% versus 75%, respectively
P  .05).
onclusions: Patient–prosthesis mismatch after mitral valve replacement is not
ncommon; it is associated with recurrence of congestive heart failure and postop-
rative pulmonary hypertension and independently affected late survival. This study
mphasizes the importance of implanting a sufficiently large prosthesis in adult
atients undergoing mitral valve replacement.
he concept of patient–prosthesis mismatch (PPM) was first described by
Rahimtoola1 more than a quarter of a century ago. Since that time, the
deleterious effects of PPM on left ventricular remodeling, functional status,
nd early and late survivals after aortic valve replacement have been extensively
eported.2-9
Recently, there has been increasing interest in mitral valve patient–prosthesis
ismatch (MVPPM), which has been described less often in adults but is commonly
ncountered in the pediatric population.10-12 MVPPM was identified in case report13
ut has subsequently been more clearly defined using echocardiographic parameters
s an indexed effective orifice area (IEOA) of 1.2 to 1.3 cm2/m2 or less.14,15 The
iovascular Surgery ● June 2007
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CDlinical problems associated with adult MVPPM have not
een detailed but seem to include postoperative pulmonary
ypertension (PHTN) and increased early mortality, al-
hough the latter has been disputed.16-18
The objectives of this study were to determine (1) the
ncidence of MVPPM and (2) the impact MVPPM on re-
urrent congestive heart failure (CHF), postoperative
HTN, and late survival.
Abbreviations and Acronyms
EOA  effective orifice area
GOA  geometric orifice area
IEOA  indexed effective orifice area
IGOA  indexed geometric orifice area
MVPPMmitral valve patient–prosthesis mismatch
MVR mitral valve replacement
PHTN  pulmonary hypertension
PPM  patient–prosthesis mismatch
RVSP  right ventricular systolic pressure
SPAP  systolic pulmonary artery pressure
ABLE 1. Patient characteristics
All
haracteristic n  884 (%)
emography
Female 521 (59)
Age (y, mean  SD) 63 12
Body surface area (m2) 1.8  0.2
EOA (cm2) 2.6  0.6
IEOA (cm2/m2) 1.5  0.4
ardiac comorbidity
Atrial fibrillation 323 (37)
Previous cardiac surgery 145 (16)
CAD 300 (34)
NYHA class III and IV 525 (59)
LV class III and IV 212 (24)
Mitral stenosis 371 (42)
Mitral regurgitation 248 (28)
Mix stenosis/regurgitation 265 (30)
ssociated procedure
CABG 263 (30)
1 99 (11)
2 81 (9)
3 83 (10)
EOA (cm2/m2)
1.25 0
1.26-1.50 289 (33)
1.51-1.75 123 (14)
1.76-2.0 106 (12)
2.0 86 (9)
OA, Effective orifice area; IEOA, indexed effective orifice area; CAD, coron
oronary artery bypass grafting; SD, standard deviation; MVPPM, mitral valve p
The Journal of Thoracicaterials and Methods
atients
etween 1985 and 2005, 884 patients, with a mean age of 63 12
ears (range 20-90 years, median 65 years), underwent mitral
alve replacement (MVR) at the University of Ottawa Heart In-
titute. The methods of data collection and analysis of the Univer-
ity of Ottawa Heart Institute Valve Clinic database were reviewed
nd approved by the University of Ottawa Heart Institute Human
esearch Ethics Board. Patient demographics and characteristics
re outlined in Table 1.
Standard surgical techniques were used, including cardiopul-
onary bypass, mild systemic hypothermia, and access through a
edian sternotomy. Cardioplegic arrest was achieved with blood
ardioplegia or a modified St Thomas crystalloid cardioplegic
olution. Valve sizing and prosthesis brand selection were per-
ormed in accordance with guidelines provided by the manufac-
urers and at the discretion of the surgeon. The valves implanted
ncluded On-X (Medical Carbon Research Institute, Austin, Tex),
t Jude Medical (St Jude Medical Inc, St Paul, Minn), Carbomed-
cs (Sorin Biomedica, Via Crescentino, Italy), Medtronic Hall
Medtronic, Minneapolis, Minn), Carpentier-Edwards Perimount
Edwards Lifesciences, Irvine, Calif), and Medtronic Hancock II
Medtronic) (Table 2). Concomitant coronary artery bypass graft-
ng was performed when indicated.
NO MVPPM MVPPM
n  604 (%) n  280 (%) P
381 (73) 140 (27) .0002
63  12 65 11 .08
1.7  0.2 1.9 0.2 .0001
2.8  0.5 2.1 0.2 .0001
1.6  0.3 1.1 0.1 .0001
248 (41) 76 (27) .0001
112 (19) 33 (12) .03
192 (29) 108 (39) .05
368 (61) 157 (56) .06
149 (25) 63 (23) .1
262 (44) 109 (39) .3
157 (26) 91 (33) .04
187 (31) 78 (28) .4
156 (26) 107 (38) .002
59 (10) 40 (14)
52 (8) 29 (10)
45 (8) 38 (14)
280 (32) 129 (57) .0001
0 41 (18) .0001
0 51 (23) .0001
0 4 (2) .0001
0 2 (1) .0001
rtery disease; NYHA, New York Heart Association; LV, left ventricle; CABG,ary a
atient–prosthesis mismatch.
and Cardiovascular Surgery ● Volume 133, Number 6 1465
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A
CDollow-up
he University of Ottawa Heart Institute Valve Clinic prospec-
ively follows all surgical valve recipients. At each annual visit, all
atients underwent a medical history focused on the determination
f functional status and the occurrence of valve-related complica-
ions, a physical examination, laboratory testing (complete blood
ount, chemistry, international normalized ratio), electrocardio-
ram, and chest radiography. Prosthesis-related complications
ere recorded according to the Guidelines for Reporting Morbid-
ty and Mortality after Cardiac Valvular Operations.19 The mean
ollow-up was 5.1  4.1 years (4344 patient-years, median 3.8
ears, maximum 19 years) and complete.
In addition, 746 patients (84%) underwent a complete M-mode,
-dimensional, and Doppler transthoracic echocardiogram at their
rst annual follow-up appointment and subsequently as clinically
ndicated per the recommendations of the American College of
ardiology/American Heart Association/American Society of
chocardiography 2003 Guideline Update for the Clinical Appli-
ation of Echocardiography.20 Postoperative follow-up transtho-
acic echocardiographic recordings of systolic pulmonary artery
ressure (SPAP) were available on a subset of 518 patients (59%).
ardiac dimensions, gradients, and estimation of right ventricular
ystolic pressure (RVSP) and SPAP were assessed with continuous-
ave Doppler. For SPAP, the maximum peak TR velocity (V) re-
orded from any view was used to determine the RVSP with the
implified Bernoulli equation (RVSP  4V2  radial artery pres-
ure), with radial artery pressure assumed to be 10 mm Hg. SPAP
as assumed to equate the RVSP in the absence of pulmonary
tenosis and right ventricular outflow tract obstruction. The mean
nterval to the follow-up echocardiograms was 5.2  3.7 years
ABLE 2. Prostheses implanted with respective effective
EOA (c
(cm
n
echanical 6
2.5
n-X (Medical Carbon Research Institute, Austin, Tex) 85
2.4
t Jude Medical (St Jude Medical Inc, St Paul, Minn) 209
2.2
arbomedics (Sorin Biomedica, Via Crescentino, Italy) 121
2.3
edtronic-Hall (Medtronic, Minneapolis, Minn) 242
3.1
ioprosthesis 2
2.2
arpentier-Edwards Perimount (Edwards Lifesciences,
Irvine, Calif)
24
2.4
edtronic Hancock II (Medtronic) 203
2.1
OA, Effective orifice area; IEOA, indexed effective orifice area.range 0.5-19 years, median 5.1 years). w
466 The Journal of Thoracic and Cardiovascular Surgery ● Junitral Valve Patient–Prosthesis Mismatch Definition
he calculation of the indexed valve area has been somewhat contro-
ersial. Some reports have used the geometric orifice area (GOA)17,18
rovided by the manufacturer as a base value, whereas other reports
ave used the effective orifice area (EOA) measured in vivo.14,15 To
void confusion, the indexed valve area will be referred to specifically
s indexed GOA (IGOA) or IEOA. In this study, we used the latter
ethod because of its known clinical correlation with clinical out-
omes and more accurate estimation of postoperative gradients.21 The
EOA was obtained by dividing the valve’s in vivo EOA (centimeters
quared), provided by the manufacturer or obtained from the litera-
ure, by the patient’s calculated body surface area (meters squared).
hen more than 1 EOA was available, the mean value was used in
he calculation of IEOA. By using these criteria and the work by Li
nd colleagues,16 in which MVPPM was defined as an IEOA of 1.2
o 1.3 cm2/m2 or less, we defined MVPPM as any IEOA of 1.25
m2/m2 or less. The selection of this value was also based on the lack
f clinical effect in our statistical modeling with IEOA values of 1.5
m2/m2, 1.4 cm2/m2, and 1.3 cm2/m2.
efinition of Outcomes
rimary outcomes in this study included (1) the recurrence of CHF
s defined by New York Heart Association functional class 3 or 4
or more than 4 consecutive weeks or death where the primary
ontributing diagnosis was CHF; (2) postoperative PHTN as an
PAP greater than 40 mm Hg as measured by echocardiography;22
nd (3) late survival as a patient censored at a minimum of 30 days
fter surgery.
ata Analysis
escriptive statistics were used to summarize data. Categoric data
e areas and indexed effective orifice areas
OA
Size 25 Size 27 Size 29 Size 31 Size 33
46 116 202 192 101
2.2/1.24 2.4/1.46 2.6/1.51 2.6/1.46 2.7/1.35
33 (72) 29 (25) 2 (1) 16 (8) 5 (5)
2.4/1.33 2.4/1.39 2.4/1.37 2.4/1.31 2.4/1.11
4 (9) 36 (31) 69 (34) 60 (32) 40 (40)
1.9/1.15 2.2/1.32 2.3/1.33 2.4/1.36 2.4/1.23
0 15 (13) 42 (21) 39 (20) 25 (25)
2.4/-- 2.4/1.39 2.3/1.28 2.2/1.19 2.3/1.17
9 (19) 36 (31) 89 (44) 77 (40) 31 (30)
2.2/1.24 2.7/1.72 3.5/2.07 3.5/1.97 3.5/1.89
17 47 81 60 22
1.7/0.90 1.9/1.13 2.3/1.37 2.8/1.56 2.7/1.42
0 13 (23) 11 (14) 0 0
1.8/-- 1.9/1.17 2.7/1.63 2.8/-- 2.8/--
17 (100) 34 (72) 70 (86) 60 (100) 22 (100)
1.5/0.90 1.8/1.09 1.9/1.11 2.8/1.56 2.6/1.42orific
m2)/IE
2/m2)
(%)
57
/1.41
(13)
/1.30
(32)
/1.28
(18)
/1.26
(37)
/1.78
27
/1.31
(11)
/1.4
(89)
/1.22ere described using frequencies and percentages; comparisons
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A
CDere made using the chi-square test or the Fisher exact test when
he frequency was less than 5. Continuous variables were pre-
ented as mean  standard deviation, and comparisons of contin-
ous variables were performed using the Student t test for nor-
ally distributed data and the Wilcoxon rank-sum test when
alues were skewed. Exploratory correlation analyses were per-
ormed using the Spearman (rs) correlation coefficient.
The Kaplan–Meier method was used to assess time-related
utcomes (freedom from CHF, freedom from postoperative
HTN, and survival). Predictors of outcomes were identified using
 semiparametric multivariable Cox proportional hazard model;
ariables screening ensured that an adequate (n  10) number of
vents were associated with a potential risk factor and that the
cales of ordinal and continuous variables were calibrated with
espect to outcome. Variable selection proceeded in a forward
tepwise manner with a liberal entry criterion of P less than .1 and
 stay criterion of P equal to or less than .05. Logistic regression
as applied to determine the effect of valve type (mechanical,
ioprosthesis), valve size criteria (manufacturer size, calculated
EAO), and echocardiographic parameters (mean and peak mitral
radients, SPAP) on the cumulative rate of recurrent CHF and
ostoperative PHTN. All time-related estimates are considered
eliable to 10 years. All analyses were performed using the SAS
tatistical software (SAS v9.1; SAS, Cary, NC).
esults
itral Valve Patient–Prosthesis Mismatch
here were 280 patients (32%) with an IEOA of 1.25
m2/m2 or less, meeting the definition of MVPPM (Table 1).
he proportion of patients with MVPPM was lower in those
ith mechanical valves than those with bioprostheses (23%
s 57%, P  .0001). A higher proportion of patients with
echanical valves had an IEOA greater than 1.50 cm2/m2
39% vs 26%, P  .0001).
utcomes
Recurrence of congestive heart failure. The overall
reedom from recurrence of CHF at 1, 3, 5, and 10 years was
8%, 96%, 94%, and 85%, respectively (Figure E1). In
atients with MVPPM, 1, 3, 5, and 10-year rates were
ignificantly less than patients without MVPPM (P 
0001) (Figure 1, A). Predictors of recurrent CHF included
ow IEOA (1.0 and 1.5 cm2/m2, hazard ratio [HR] 4.0,
.6-10.4, and 3.5, 1.9-6.3), worse left ventricular function
HR 1.01, 1.0-1.03), elevated mean mitral gradient on fol-
ow-up echocardiography (HR 2.0, 1.1-3.3), and prolonged
ardiopulmonary bypass (HR 1.1, 1.01-1.1) (Table E1).
oronary artery disease, age, and peak mitral gradients on
ollow-up did not predict the return of CHF (P.05). There
as a linear effect of MVPPM (odds ratio [OR] 3.9),
ostoperative mitral gradients (OR 1.8), use of a biopros-
hesis (OR 2.7), and elevated SPAP (OR 1.02) on the
ecurrence of CHF (Appendix E1).
Postoperative pulmonary hypertension. Exploratory
orrelation matrices demonstrated an absence of linear re- C
The Journal of Thoracicationships between IEOA and mean mitral gradient, peak
itral gradient, and SPAP. In patients with MVPPM (IEAO
 1.25 cm2/m2), there was no correlation between IEOA
nd mean and peak gradients, or with SPAP; however, a
trong correlation was observed between peak mitral gradi-
nt and SPAP. In patients with an IEOA of 1.0 cm2/m2 or
ess, IEOA correlated well with mean and peak mitral
radients but not with SPAP. In general, elevated postop-
rative mean and peak mitral gradients were closely related
o SPAP. In patients with bioprostheses, a linear relation-
hip was seen between IEAO and mean mitral gradients, but
ot peak mitral gradients or SPAP.
Freedom from PHTN at 1, 3, 5, and 10 years was 99%,
6%, 93%, and 78%, respectively (Figure E2). Freedom
rom postoperative PHTN in patients with MVPPM at 1, 3,
, and 10 years was similar to that of patients without
VPPM (98% vs 99%, 97% vs 96%, 96% vs 92%, and
9% vs 78%, respectively, P  .6); however, patients with
maller sized valves ( 27) had higher rates of postopera-
ive PHTN when compared with patients with valve sizes 29
r larger (P  .005) (Figure 1, B).
Predictors of postoperative PHTN included older age
HR 1.02, 1.01-1.02), smaller valve size (HR 1.04, 1.01-
.07), low ejection fraction (HR 1.03, 1.01-1.05), elevated
ostoperative mitral gradient (HR 1.15, 1.09-0.121), atrial
brillation (HR 1.31, 1.12-1.52), and use of a bioprosthesis
HR 1.36, 1.12-1.64) (Table E1); IEOA of 1.25 cm2/m2 or
ess did not predict postoperative PHTN (HR 1.02,
.84-1.3).
Survival. Overall 1, 3, 5, and 10-year survivals were
5%, 90%, 85%, and 73%, respectively (Figure E3). Pa-
ients with MVPPM had worse 1, 3, 5, and 10-year survivals
91% vs 95%, 85% vs 90%, 78% vs 86%, and 65% vs 75%,
espectively, P  .05) (Figure 1, C). Survival in patients
ith elevated SPAP (40 mm Hg) was less than their
ounterparts with SPAP in the normal range (P  .02)
Figure E4).
Predictors of survival included older age (HR 1.10, 1.04-
.34), IEOA of 1.25 cm2/m2 or less (HR 2.4, 1.5-3.9),
reoperative CHF (HR 1.22, 1.05-1.42), presence of coro-
ary artery disease (HR 23, 3.0-175), history of stroke (HR
.7, 1.6-8.3), postoperative PHTN as defined by elevated
PAP (HR 1.1, 1.03-1.09), and implantation of a biopros-
hesis (HR 2.5, 1.3-4.7). No significant difference in
urvival was seen between patients with an IEOA be-
ween 1.01 and 1.25 cm2/m2 versus an IEOA of 1.0
m2/m2 or less (P  .17).
iscussion
he key findings of this retrospective study were as follows:
1) The incidence of MVPPM was higher than originally
nticipated; (2) MVPPM was associated with recurrence of
HF; (3) MVPPM was not directly associated with postop-
and Cardiovascular Surgery ● Volume 133, Number 6 1467
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1
A
CDrative PHTN, but smaller valve size and elevated gradients
ere directly associated with postoperative PHTN; and (4)
urvival of patients post-MVR was affected by MVPPM.
The concept of residual obstruction with persistent ele-
ated transprosthetic gradients postaortic valve replacement
as first reported by Rahimtoola in 1978.1 Since then, manyignificant contributions have led to the establishment of e
468 The Journal of Thoracic and Cardiovascular Surgery ● Junrecise diagnostic criteria and to the development of pre-
entative strategies to avoid PPM in the context of aortic
alve replacement.21,23 The negative effects of aortic valve
PM on left ventricular remodeling, functional status, early
ortality, and late survival have been extensively corrobo-
ated.2-9 What remains uncertain is whether clinically del-
Figure 1. A, Freedom from recurrent
CHF: MVPPM versus NOMVPPM (P <
.0001). B, Cumulative incidence of post-
operative PHTN: smaller sized valve
(<27) versus larger (>29) sized valve (P
 .005). C, Adjusted survival according
to MVPPM versus NOMVPPM (P  .05).
CHF, Congestive heart failure; PHTN, pul-
monary hypertension; MVPPM, mitral
valve patient–prosthesis mismatch.terious effects of PPM could be encountered after MVR.
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CDitral Valve Patient–Prosthesis Mismatch
here has been a recent mounting interest in MVPPM,
hich has been well documented in the pediatric popula-
ion. In the latter, mitral valve re-replacement rates upward
f 27% have been reported because somatic growth has led
any children to outgrow their mitral valve prosthesis.10,12
variety of factors have been used in an attempt to define
he concept of clinical MVPPM in childre: These have
ncluded size/weight ratios, Z scores, maximum transpros-
hesis velocity (Vmax), and 2.5 times increase in body
eight from the time of implant. In all instances, these
actors have been correlated with outcomes (early mortality,
urvival, and PHTN).10-12
Adult MVPPM was the subject of an original case report
n 1981;13 it has subsequently been theorized, through in
itro pulse duplicator analysis, that an IGOA less than 1.3 to
.5 cm2/m2 could potentially leave the patient with high
ostoperative transprosthetic gradients unrelated to struc-
ural dysfunction.14 In a clinical study, a good correlation
etween elevated transprosthetic mitral gradient and in vivo
EOA was demonstrated by the use of the continuity equa-
ion during echocardiographic assessment of porcine mitral
rostheses.15 In this report, an IEOA of 1.3 to 1.5 cm2/m2 or
ess at rest was associated with a mean mitral gradient of 4
m Hg; with every 10% increase in stroke volume (maxi-
um 50%), there was a proportional increase of the mean
itral gradient (eg, IEOA  1.0 cm2/m2, 50%, mean
itral gradient of 14 mm Hg). In our study, we had an
ncidence of MVPPM (IEOA  1.25 cm2/m2) of 32% with
% of patients having an IEOA less than 1.0 cm2/m2.
itral Valve Patient–Prosthesis Mismatch and
ongestive Heart Failure Recurrence
he unadjusted 1, 5, and 10-year cumulative incidence of
ecurrent CHF post-MVR was 2%, 6%, and 15%, respec-
ively; the rates were significantly higher (5%, 15%, and
8%, respectively) when adjusted for MVPPM criteria.
hese results are similar to those we previously reported
nd take into further consideration the indexed in vivo EOA
ather than only prosthesis size.24 CHF was 3.5 and 4 times
ore likely to develop postoperatively in patients with an
EAO of 1.0 cm2/m2 or less and an IEAO of 1.25 cm2/m2 or
ess, respectively. Elevated mean mitral gradients were as-
ociated with recurrence of CHF. Although an IEOA of 1.25
m2/m2 or less and elevated mean mitral gradients predicted
he recurrence of CHF, no direct significant correlation was
stablished between these 2 variables (rs  0.12, P  .1).
his finding was in contrast with work from Dumesnil and
olleagues15 and Li and colleagues16 that described a mod-
rate level of correlation between IEOA and transprosthetic
radients (r  0.46-0.63). This weaker correlation could be
ue to the smaller proportion of patients with prostheses less
han 27 mm (26% vs 52%16 and 69%15) observed in our
tudy; this could considerably decrease the risk of elevated c
The Journal of Thoracicransprosthetic gradients developing in patients and thereby
mpacting the establishment of a correlation. A second
otential reason for this would be the dependency of
ransprosthetic gradients on transvalvular flow rate, a de-
endent factor of diastolic filling time, which is in return
ensitive to the effect of chronotropy. In this context, the
stablishment of good correlations between IEOA and
ransprosthetic gradients is more difficult post-MVR than
ortic valve replacement.
In our study, in view of the high proportion of patients
76%) with class I and II left ventricular function preop-
ratively, the effect of left ventricular function on recur-
ence of CHF was noted as marginal (HR 1.01). As in
atients with aortic valve PPM, we must not discount the
otential impact of left ventricular function on outcomes
ost-MVR.3,25
Postoperative PHTN was weakly associated with the
ecurrence of CHF; overall, the mean SPAP of patients with
HF was greater than that of their counterparts (47.6 11.3
s 42.8  13.4 mm Hg, P  .04). In patients with recurrent
HF, there was no correlation between IEOA and SPAP
P  .6). The known detrimental impact of residual or
ecurrent PHTN, due to mitral valve disease, on functional
utcome and survival has been reported.25-28
itral Valve Patient–Prosthesis Mismatch
nd Postoperative Pulmonary Hypertension
he unadjusted 1, 5, and 10-year cumulative incidence of
ostoperative PHTN was 1%, 7%, and 22%, respectively;
nce adjusted for smaller mitral valve size (27), the rates
ere higher in patients with size 25 and 27 prostheses at 1,
, and 10 years (2% vs 1%, 18% vs 4%, 33% vs 20%,
espectively, P  .005). When we looked at 1, 5, and
0-year rates of postoperative PHTN in patients with
VPPM versus NOMVPPM, there was no difference (2%
s 1%, 4% vs 8%, 31% vs 22%, respectively, P .6). These
esults sharply contrasted with those reported by Li and
olleagues,16 showing a postoperative PHTN prevalence
ate of 68% in patients with MVPPM. This difference, along
ith the lack of correlation between IEOA and SPAP (rs 
.03, P  .4), could be attributable to several factors: First,
he proportion of patients in our study who received smaller
ized prostheses (25 and 27) was 26% (mechanical 25%,
ioprosthesis 28%) in comparison with the 52% reported.
his might constitute an unusually elevated proportion by
urrent standards.24,29,30 This would mean that 29 of the 56
atients in Li and colleagues’ study were already at a higher
isk of having MVPPM and postoperative PHTN; this was
onfirmed by the elevated incidence of MVPPM (71%).
econd, the population selected by Li and coworkers, be-
ause of the greater proportion of smaller valves, would take
onger to normalize any preoperative PHTN and would
herefore be subject to higher postoperative SPAP, espe-
ially in patients with MVPPM, thus possibly strengthening
and Cardiovascular Surgery ● Volume 133, Number 6 1469
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CDhe correlation between IEOA and SPAP that the authors
escribed. In contrast, our patients had an almost equal
roportion of patients with PHTN irrespective of MVPPM
djustments (57% vs 55%, P  .2). Third, there is the issue
f body surface area; the mean body surface area of our
atients without MVPPM was 1.76  0.18 m2, a number
lmost equivalent to Li and colleagues’ group of patients
ith MVPPM (1.75  0.16 m2). This would lead us to
onclude that a significant proportion of patients with bor-
erline body surface area likely did not receive a valve
ufficiently large enough, thus predisposing them to
VPPM. Finally, a point of concern is the fact that the rate
f postoperative PHTN was observed to be increasing over
ime, leading us to question the exact contribution of other
onfounders (age, atrial fibrillation, type of prosthesis, and
eft ventricular function).
The IEAO was not predictive of postoperative PHTN,
ut its surrogate marker (valve size  27) and elevated
ean mitral gradients were. This lack of correlation could
e explained by the incomplete reporting of SPAP in the
chocardiograms collected. In a similar analysis in children,
asuda and colleagues12 reported the absence of correlation
etween IGOA and catheterized pulmonary artery wedge
ressure; however, good correlation was seen between max-
mal transprosthetic flow velocity (Vmax) and IGOA and
etween Vmax and catheterized pulmonary artery wedge
ressure. It has been postulated that MVPPM post-MVR
ay predispose one to persistence of high afterload on the
ight ventricle, resulting in stunning and right ventricular
ailure leading to increased early mortality.17 This may be
xtrapolated to patients with MVPPM and a chronic decline
f right ventricular function over time, which would ulti-
ately lead to right ventricular failure and death.
In view of the relative inconsistency of the relationships
etween PHTN markers (SPAP, IEOA, Vmax, pulmonary
edge pressure, transprosthetic gradients, and pulmonary
ascular resistance and compliance) reported here and in the
iterature, further data are required to elucidate the potential
echanistic and hemodynamic ramifications of PHTN post-
VR and its impact on clinical outcomes.
itral Valve Patient–Prosthesis Mismatch and
urvival
he overall survival for our cohort of patients post-MVR
as acceptable and approached 75% at 10 years. The 1, 5,
nd 10-year survivals for patients with MVPPM were sig-
ificantly worse than those of their counterparts. Fernandez
nd coworkers18 were among the first to report on the
linical implications of MVPPM; however, in their study,
he GOA, which often overestimates the valve area, was
sed to calculate the IGOA. They did not find any associ-
tion between indexed valve area and early and late mor-
idity or late mortality. A second report by Yazdanbakhsh
nd colleagues17 on the impact of IGOA on outcomes stated p
470 The Journal of Thoracic and Cardiovascular Surgery ● Junhat the lower tail end of IGOA ( 1.9 cm2/m2) was
ssociated with early mortality (HR 4.3, 1.6–9.5) but had no
ffect on late mortality. Once again, the GOA was used in
he calculations of IGOA and may have led to overestima-
ion of IGOA and thus biased the effect of the latter on late
ortality. In our study, an IEOA of 1.25 cm2/m2 or less was
predictor of poor late survival. As previously stated, we
elieve that the IEOA is a better prognostic indicator than
he IGOA because it has been shown to be a reliable
redictor of clinical outcomes.21 We must caution that, as is
he case in most retrospective studies, a finding of associa-
ion does not automatically imply causation. The presence
f other significant clinical correlates (age, coronary artery
isease, left ventricular function, preoperative CHF, and
HTN) to survival would indicate a multifactorial cause that
ill require further elucidation.
imitations
his is a single-institution, nonrandomized, observational
linical study in which group differences and known con-
ounders were controlled for in the multivariable analysis.
espite the large sample size and statistical adjustments
pplied, unmeasured and unknown confounders may have
nfluenced the results. Nonsystematic echocardiographic
ollow-up of patients represents an important limitation of
his study because missing echocardiographic data (echo-
ardiographic predictors of MVPPM) may have had an
mportant impact on clinical outcomes. In addition, an un-
erreporting of SPAP on follow-up echocardiograms may
ave resulted in an underpowered assessment of correlation
etween IEOA and PHTN.
We have made all efforts to use primarily only published
OAs rather than GOAs in the calculation of IEOA values.
owever, because of the limited availability of reports on
itral EOAs for all of the valve types and brands, we did
ot discriminate against EOA values obtained by the pres-
ure half-time method; this latter is known to overestimate
OAs. When an EOA for a particular valve brand and size
as not available, we had to use the GOA. These 2 condi-
ions may have led to an underestimation of the true inci-
ence of MVPPM in this cohort of patients.
Furthermore, Cox proportional hazards models require an
ssumption of independent censoring that may not always be
et. In this regard, it is possible that patients lost to follow-up
fter a number of visits may have had subsequent outcomes
hat were not accounted for in the analyses. Similar to that of
ther observational cohorts, the results of these analyses may
ot be generalizable to all patients who have undergone pros-
hetic valve replacement at other centers.
Finally, as mentioned previously, in view of the relative
nconsistency and scarce amount of information on the
elationships between PHTN markers (SPAP, IEOA, Vmax,
ulmonary wedge pressure, transprosthetic gradients, pul-
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CDonary vascular resistance, and compliance), further data
ill be required to elucidate the potential mechanistic and
emodynamic ramifications of PHTN post-MVR.
onclusions
ur results suggest that a threshold exists below which out-
omes are negatively impacted by the insertion of a smaller
han acceptable valve; however, contrary to aortic valve PPM,
here are limited operative solutions to alleviate the problem of
VPPM. Possible alternatives, such as stentless mitral pros-
heses and homografts, require expertise and experience, thus
imiting their use in this context. Surgeons would be best
erved to be aware of this to guide valve selection toward the
argest available EOA valve for annulus size, irrespective of
alve type or brand; this latter point is even more important
hen implanting a bioprosthesis, which we have observed to
e more prone to MVPPM. Finally, this study reemphasizes
he importance of mitral valve repair as the preferred thera-
eutic option whenever possible.
This study constitutes an initial report associating IEOA
ost-MVR and clinical outcomes (recurrent CHF, postop-
rative PHTN, and late survival). By using an IEOA of 1.25
m2/m2 or less as a cutoff point to define MVPPM, we
emonstrated that the incidence of MVPPM was higher than
nticipated. We also determined that patients with MVPPM
ere 4 times more likely to experience recurrent CHF.
VPPM was also associated with postoperative PHTN
SPAP  40 mm Hg), although smaller valve size rather
han IEAO was a predictor of PTHN. Finally, MVPPM was
ssociated with a decrease in late survival.
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iscussion
r F. Crawford (Charleston, SC): Drs Feindel and Mitchell, I
ave no conflicts to disclose. I enjoyed this presentation very
uch. PPM after aortic valve replacement has been discussed at
ength in recent years, although there is far from universal agree-
ent about the potential implications of such mismatch. Far less
nformation is available about PPM in the mitral position. Several
mportant differences between the aortic and mitral position exists
s indicated by the authors, including limited options for implant-
ng large valves in the mitral positions and inferior types of
rostheses available for MVR. In addition, PPM in the aortic
osition may adversely affect left ventricular function, whereas in
he mitral position it is usually right ventricular function that is
ffected.
In this excellent article that describes a large series of patients
ho underwent MVR and were followed prospectively by the
uthors, IEOA did not predict persistent PHTN, which has gener-
lly been considered an important factor predicting outcomes after
VR. I have several questions for the authors.
If PHTN was not associated with PPM, what do you postulate
s the reason for the poorer outcomes in your patients?
Second, what percentage of your patients had chordal-sparing
VR, and was the lack of such a chordal-sparing procedure an
ndependent risk factor for poorer outcomes?
Finally, in the article you state, “We recommend avoidance of
bioprosthesis in patients with possible MVPPM criteria.” Does
his mean that you would therefore recommend using a mechanical
rosthesis in such a patient even if the patient were elderly and that
ou therefore believe the potential risk of MVPPM in such a
atient outweighs the known risk of long-term anticoagulation
ith Coumadin?
Dr Lam: With regard to the lack of correlation between the
EOA and PHTN in this study, I must say that although our
ollow-up is prospective in nature and we gather as many echo-
ardiograms as we can, when we look at the data with regard to the
vailability of the SPAP, these are not always reported consistently
n all of our echocardiogram reports. Therefore, we are likely
nderpowered to detect the link between IEOA and PHTN. This
ould mean that some of our patients, who had lower IEOAs or
OAs, likely did not have the PHTN variable available for anal-
sis.
With regard to the possible explanations as to why patients with
HTN do not fare as well; it is difficult to explain. I think that, at
his point, the correlation between IEOA and other echocardio-
raphic markers, such as gradients or PHTN, remains unclear in
he literature. Some studies have found correlations, and others
ave not. At this point I can’t tell you for sure what would be an
dequate marker to be associated with a worse IOA, whether it can
e the gradients, PHTN, or aortic valve compliance. The latter has
een suggested as a newer potential clinical marker that could be
onitored. Once these markers are established, we still have toorrelate them with clinical outcomes. s
472 The Journal of Thoracic and Cardiovascular Surgery ● JunWith regard to your question on chordal preservation, this study
s somewhat historical in nature and spans 20 years. Certainly our
ractice currently is to do chordal preservation, but that has
hanged over the years and that data are not entirely available in all
atients, so therefore I am not able to answer that question.
With regard to the use of biological valves, I think that we
urrently abide by all the guidelines with regard to the use of an
ppropriate valve for the patient size and risk factors. There are
arious sizes in terms of valves, and each valve brand has an EOA
hat is variable. I think the take-home message is that we should try
nd insert the largest EOA valve possible irrespective of brand,
nd that varies from one brand name to the other. Certainly we
ould not subject a patient to the undo risk of anticoagulation if
e found an adequate sized biological valve for the annulus.
Dr R. Martinez-Sanz (Tenerife, Spain): In mitral insufficiency
hen a mitral ring is performed, the aim is to reduce the posterior
nnulus, undersizing this as much as 26 mm, 28 mm, or less. For
his reason, when mitral repair is not possible, we perform MVR
sing a 27- or 25-mm valve prosthesis with less hospital mortality
nd postoperative complications than when using a bigger pros-
hesis. Now we are studying the follow-up of this class of patients.
The question is, in your study, do you know how many patients
ith undersized prostheses there were?
Dr Lam: To answer your question, this table illustrates the in
ivo EOA used in this study according to valve and valve size; as
ou can see, some of these valves, highlighted in green, have
maller EOAs to begin with. Once this is indexed, there is a
ariability with regard to each valve, and this is, of course, depen-
ent on your patient population, but this is our patient population
nd what their index was. So the green areas are the areas of
rouble, and we have noticed them in this type of valve, the
ioprosthesis, and we have noticed them in the larger patients.
Now, the larger patients, one of the things that we do know is
hat the literature has few EOA publications and the sample sizes
re relatively small. So we are going by a small number, but it
eems to suggest that for the larger sized patients, the valves that
re out there right now may not have an appropriately sized EOA,
nd that is what we found in our study.
Dr Martinez-Sanz: This is for the whole group, not for the
itral regurgitation group only?
Dr Lam: I unfortunately do not have data for the mitral
egurgitation group specifically.
Dr E. Jamieson (Vancouver, Canada): Congratulations for
ringing this topic forward. Some of my questions have been
nswered, but a couple are, how confident are you that a break-off
f 1.25 does not require further investigation? The second has been
artially answered by your last slide, but the other question is
elated to your large experience with the On-X valve. As we all
now, the size of the orifice is 25 mm regardless of whether you
re using a 25 or 31; how did you handle that and did you find any
iscrepancies in performance?
Dr Lam: With regard to the On-X valve, you are right, the
alve in this scenario seemed to perform adequately except for the
arger sized valves, and as I just mentioned, I think that this needs
o be revisited in terms of an appropriately sized valve for a larger
atient per se. We have done the analyses on various segments of
EOAs, going from 1.5 to 1.0 cm2/m2. Clinical correlations are
trongest when you hit 1.0 cm2/m2. However, I think that in terms
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CDf clinical outcomes, the significant cutoff in this study was ap-
roximately 1.25 cm2/m2, and that is why we used the 1.25
m2/m2. The range that is given in the literature varies from 1.2 to
.5 cm2/m2, and that is based on pulse duplicator data on small
ample sizes to establish echocardiographic correlations. To put
hat into a clinical context, we had to do the analysis over a wide
ange of IEOAs.
Dr Pasquale Totaro (Palermo, Italy): First of all, I congratu-
ate you for addressing such an important issue that has been
lmost ignored for a long time. I have done a similar study, and I
m going to present my results during an European meeting in due
ourse. The data I am going to present are different from the data
ou presented today. By using only stented Carpentier-Edwards
ioprosthesis and evaluating the PPM based on the postoperative
n vivo IEOA, we found an incidence of PPM less than 10%, and
his included patients with a size 25 bioprosthesis.
Did you evaluate PPM on the basis of in vivo postoperative
chocardiogram data on your patients? Did you find any difference
etween mechanical and biological prostheses?
Dr Lam: We have not performed the analysis yet, but the data
re available. We didn’t look at that specifically. We specifically
ooked at our MVPPMs and what their gradients were, but that is
n excellent point.
I think that when you look at the data with regard to EOA, there
re 2 ways to go about it: (1) Ask your echocardiographer to
ctually do the measurements by the continuity equation, not the
ressure half time, which is not as reliable. (2) Review the litera-
ure and garner all the EOAs possible that were published based on
n vivo echo measurements and not laboratory or pulse duplicator
ata, which are sometimes what you get when you get the little d
The Journal of Thoracicamphlet from the companies giving you different EOAs. If the
atter is what you have done, then we should probably have to
ompare our mutual results.
Dr Totaro: So these are not data that you calculated in vivo
ostoperatively?
Dr Lam: No. We used averaged EOAs from the studies in the
iterature.
Dr Totaro: I think that this could make a real impact and
xplain the difference between our results .
Dr Guo-Wei He (Hong Kong, China): Dr Lam, this is an
mportant study, particularly, as Dr Crawford says, the mitral valve
nd the patient mismatch was not the same as the aortic valve and
he patient mismatch. A few years ago we published a study in the
ournal on aortic valve mismatch with patient body surface area,
nd what we found was with a body surface area more than 1.6,
hen you use a small aortic prosthesis, including a 19- and a
0-mm prosthesis, there was less long-term survival.
Your study is interesting and scientifically accurate, but in
linical practice to use your study to look at EOA is complicated
or a practicing surgeon. Can you simplify your study to look at,
hen a patient’s body surface area is more than 1.5, 1.6, 1.7, and
.8, a small mitral size such as 25 plus 27 compared with the larger
roup? To simplify your results, can you do it that way, or maybe
ou have done that?
Dr Lam: That is definitely possible to do. We have the data set,
nd it wouldn’t be out of the scope of the completion of this
roject. I think that in terms of clinical information it would be
uch easier to interpret, as you said, and that is something we willefinitely look into.
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CDPPENDIX E1. Logistic regression analysis of valve
arameter effects on congestive heart
ailure recurrence
actor Coefficient  SD P Odds ratio (CL)
EAO  1.25 cm2/m2 1.4  0.29 .0001 3.9 (2.2-6.9)
ioprosthesis implantation 0.79 0.38 .04 2.7 (1.1-6.5)
levated mean gradient 0.61 0.26 .02 1.8 (1.1-3.1)
levated SPAP 0.02 0.01 .05 1.02 (1.01-1.05)
D, Standard deviation; CL, confidence limit; IEAO, indexed effective orifice
rea; SPAP, systolic pulmonary artery pressure.473.e1 The Journal of Thoracic and Cardiovascular Surgery ● JABLE E1. Predictors of outcomes
actor Coefficient  SD P
ecurrent CHF
IEOA  1.0 cm2/m2 1.39 0.48 .004
IEOA  1.25 cm2/m2 1.26 0.29 .0001
Low EF 0.02 0.001 .05
Elevated mean
mitral gradient
0.59 0.26 .02
Prolonged CPB 0.01 0.003 .03
PHTN 0.90  0.62 .14
Elevated peak mitral
gradient
0.04 0.07 .59
ostoperative PHTN
Older age 0.02 0.003 .0001
Smaller sized valve 0.04 0.02 .01
Low EF 0.06 0.03 .03
Elevated mean
mitral gradient
0.13 0.03 .0001
Bioprosthesis 0.31 0.09 .002
Atrial fibrillation 0.26 0.08 .0008
IEOA  1.25 cm2/m2 0.02 0.1 .89
urvival
Older age 0.20 0.05 .04
IEOA  1.25 cm2/m2 0.87 0.25 .0005
Preoperative NYHA
class 3 or 4
0.21 0.08 .009
CAD 3.14 1.03 .002
CVA 1.30 0.41 .002
Prolonged CPB 0.006 0.002 .003
PHTN 0.06 0.02 .0001
Bioprosthesis 0.90 0.33 .006
EOA, Indexed effective orifice area; EF, ejection fraction; CPB, cardiopul-
onary bypass; PHTN, pulmonary hypertension; NYHA, New York Heart
ssociation; CAD, coronary artery disease; CVA, cerebrovascular disease;une 2007
Lam et al Surgery for Acquired Cardiovascular DiseaseFigure E1. Freedom from recurrence of CHF. Mean (solid line)  95% confidence interval (CI) (dashed line). CHF,
Congestive heart failure.A
CDFigure E2. Freedom from postoperative PHTN. Mean (solid line)  95% CI (dashed line). PHTN, Pulmonary
hypertension.Figure E3. Overall survival. Mean (solid line)  95% CI (dashed line).The Journal of Thoracic and Cardiovascular Surgery ● Volume 133, Number 6 1473.e2
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CDFigure E4. Adjusted survival according to high SPAP v
pressure.ersus low SPAP (P  .02). SPAP, Systolic pulmonary artery473.e3 The Journal of Thoracic and Cardiovascular Surgery ● June 2007
